Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

. It can cause pain, discomfort, and disfigurement and may produce serious physical and occupational limitations. It is one of the most common dermatological diseases, affecting an estimated 30 million people in the USA alone while prevalence is steadily increasing for various reasons, e.g. the aging of the population, diabetes etc.

Oral therapies that are effective for treating OM include Novartis's Lamisil (R) (terbinafine) and J&J's Sporanox(R) (itraconazole). However, patients are reluctant to adopt this systemic modality for an essentially superficial disease particularly in view of lengthy treatment times and concerns regarding potential toxicity and side effects.

Approved topical treatments for OM include ciclopirox lacquer (Sanofi-Aventis's Batrafen(R) in EU; Penlac(R) in the US) and amorolfine lacquer (Galderma's Loceryl(R); EU), however, both drugs show low efficacy primarily due to the poor bioavailability in the nail bed. A safe and effective topical treatment would be expected to gain a significant market share as it would satisfy a medical need coupled with a strong patient demand.

Total revenues in this indication are ca. USD 2 billion per year and are forecast to grow based on the increasing prevalence of OM. Moreover, due to a lack of effective topical treatments and issues inherent to long term use of oral treatments, a large proportion of patients remain untreated and consequently the addressable potential market is much larger. Novartis's Lamisil(R) is the current market leader with revenues of USD 978 million in 2006.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial in an NDA-filing process and an antifungal in Phase III.

Arpida's leading product
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... 2014 2013 was a banner year ... Technologies®. They saw continued independent research led by the ... awarded a $1 million grant from the Susanne Marcus ... Behavior” a peer reviewed journal, Amy Grant highlighted Brainwave ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
(Date:4/17/2014)... such as heart disease, epilepsy and pain, making them ... is still much scientists do not know about the ... into the structure of sodium channels and, specifically, one ... responsible for ,fine-tuning, the activity of the channel. The ... the Journal of Biological Chemistry . , Nerves ...
(Date:4/17/2014)... Indiana University researchers have detected new early-warning signs of ... discovery could have far-reaching implications for the diagnosis and ... over 25 million Americans. , "We had not expected ... such early stages," said Ann Elsner, professor and associate ... author of the study. "We set out to study ...
(Date:4/17/2014)... forests are chock full of wild animals and plant ... of fungi are churning away in the soil, decomposing ... Despite the vital role these fungi play in ecological ... Stanford-led team of scientists has generated a genetic map ... America. The work was published this week in the ...
Breaking Biology News(10 mins):Structure of sodium channels different than previously believed 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3
... of the Journal of the American Medical Association ... between urine concentrations of the environmental estrogen bisphenol A ... abnormalities. In an accompanying editorial, Frederick vom Saal, a ... Administration (FDA) to follow recent action by Canadian regulatory ...
... David Lane, chairman of Singapore A*STAR,s Biomedical Research Council, ... contribution to cancer research through his discovery of p53 ... Medal is one of the highest accolades from the ... whose intellectual endeavour have made an impact on people,s ...
... press release is available in German . ... cancerous cells that appear out of the blue. But the ... system smuggle small molecules (granzymes) into cancer cells and those ... then trigger off the diseased cells, built-in suicide program. There ...
Cached Biology News:Expert urges FDA to take action to reduce BPA exposure 2Pores open the door to death 2Pores open the door to death 3
...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... Slotted migration Chamber lid allows ... One-touch connectors for easy set up ... Magnetic safety-switch prevents current flow if the lid ... Excellent safety and durability., Remote control ...
... Black wall plates have low ... reduced crosstalk,• Not treated (or medium ... nature and binds biomolecules through passive ... the immobilization of large molecules, such ...
Biology Products: